Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.

Alves-Silva JC, de Carvalho JL, Rabello DA, Serejo TRT, Rego EM, Neves FAR, Lucena-Araujo AR, Pittella-Silva F, Saldanha-Araujo F.

Invest New Drugs. 2018 Oct;36(5):955-960. doi: 10.1007/s10637-018-0613-x. Epub 2018 May 31.

PMID:
29855824
2.

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia.

Rabello DDA, Ferreira VDDS, Berzoti-Coelho MG, Burin SM, Magro CL, Cacemiro MDC, Simões BP, Saldanha-Araujo F, de Castro FA, Pittella-Silva F.

Cancer Cell Int. 2018 Feb 20;18:26. doi: 10.1186/s12935-018-0523-1. eCollection 2018.

3.

A panel of markers for identification of malignant and non-malignant cells in culture from effusions.

Carneiro FP, Muniz-Junqueira MI, Pittella-Silva F, Carneiro MV, Takano GHS, Vianna LMS, De Andrade LB, De Castro TMML, Peres I, Dos Santos Borges TK, Ferreira VM, Motoyama AB.

Oncol Rep. 2017 Dec;38(6):3538-3544. doi: 10.3892/or.2017.6022. Epub 2017 Oct 11.

PMID:
29039588
4.

Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.

Carvalho Alves-Silva J, do Amaral Rabello D, Oliveira Bravo M, Lucena-Araujo A, Madureira de Oliveira D, Morato de Oliveira F, Magalhaes Rego E, Pittella-Silva F, Saldanha-Araujo F.

Environ Mol Mutagen. 2017 Dec;58(9):654-661. doi: 10.1002/em.22128. Epub 2017 Aug 19.

PMID:
28833505
5.

Downregulation of histone methyltransferase EHMT2 in CD4+ T-cells may protect HTLV-1-infected individuals against HAM/TSP development.

Colaço CS, de Matos AR, Estrêla MS, Rocha-Júnior MC, Otaguiri KK, Rodrigues ES, Takayanagui OM, Covas DT, Kashima S, Pittella Silva F, Haddad R.

Arch Virol. 2017 Oct;162(10):3131-3136. doi: 10.1007/s00705-017-3428-8. Epub 2017 Jun 12.

PMID:
28608127
6.

Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase.

Butler KV, Ma A, Yu W, Li F, Tempel W, Babault N, Pittella-Silva F, Shao J, Wang J, Luo M, Vedadi M, Brown PJ, Arrowsmith CH, Jin J.

J Med Chem. 2016 Nov 10;59(21):9881-9889. Epub 2016 Nov 2.

7.

Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.

Oliveira-Santos W, Rabello DA, Lucena-Araujo AR, de Oliveira FM, Rego EM, Pittella Silva F, Saldanha-Araujo F.

Tumour Biol. 2016 Jul;37(7):9473-81. doi: 10.1007/s13277-016-4846-z. Epub 2016 Jan 20.

PMID:
26790435
8.

Assessment of MLL methyltransferase gene expression in larynx carcinoma.

Figueiredo DL, do Amaral Rabello D, Zanette DL, Saggioro FP, Mamede RC, Zago MA, da Silva WA Jr, Saldanha-Araújo F, Pittella Silva F.

Oncol Rep. 2015 Apr;33(4):2017-22. doi: 10.3892/or.2015.3756. Epub 2015 Jan 28.

PMID:
25633166
9.

Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.

Rabello Ddo A, Lucena-Araujo AR, Alves-Silva JC, da Eira VB, de Vasconcellos MC, de Oliveira FM, Rego EM, Saldanha-Araujo F, Pittella Silva F.

Blood Cells Mol Dis. 2015 Jan;54(1):97-102. doi: 10.1016/j.bcmd.2014.07.013. Epub 2014 Aug 15.

PMID:
25131810
10.

SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor.

Sakamoto LH, Andrade RV, Felipe MS, Motoyama AB, Pittella Silva F.

Leuk Res. 2014 Apr;38(4):496-502. doi: 10.1016/j.leukres.2014.01.013. Epub 2014 Feb 5.

PMID:
24631370

Supplemental Content

Loading ...
Support Center